Novo Nordisk A/SNVONYSE
Loading
Year-over-year research & development expense growth
Percentile
P31
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -4.84% |
| Q3 2025 | 31.68% |
| Q2 2025 | 13.41% |
| Q1 2025 | -25.32% |
| Q4 2024 | 45.47% |
| Q3 2024 | -41.31% |
| Q2 2024 | 87.85% |
| Q1 2024 | -17.72% |
| Q4 2023 | 28.69% |
| Q3 2023 | 14.05% |
| Q2 2023 | 5.93% |
| Q1 2023 | -16.78% |
| Q4 2022 | 43.53% |
| Q3 2022 | 9.96% |
| Q2 2022 | -1.59% |
| Q1 2022 | -7.56% |
| Q4 2021 | 32.46% |
| Q3 2021 | 7.81% |
| Q2 2021 | 0.00% |
| Q1 2021 | -12.02% |
| Q4 2020 | 14.63% |
| Q3 2020 | 18.84% |
| Q2 2020 | -12.87% |
| Q1 2020 | -13.85% |
| Q4 2019 | 21.74% |
| Q3 2019 | 1.24% |
| Q2 2019 | 32.82% |
| Q1 2019 | -41.07% |
| Q4 2018 | 24.70% |
| Q3 2018 | 10.56% |
| Q2 2018 | -0.75% |
| Q1 2018 | -16.62% |
| Q4 2017 | 19.68% |
| Q3 2017 | -2.52% |
| Q2 2017 | 3.80% |
| Q1 2017 | -26.42% |
| Q4 2016 | 29.27% |
| Q3 2016 | 3.81% |
| Q2 2016 | 0.82% |
| Q1 2016 | -18.10% |